Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright

HC Wainwright reiterated their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday morning,Benzinga reports.

Other equities analysts also recently issued research reports about the stock. Barclays began coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price for the company. Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Thursday, January 8th. Wall Street Zen raised Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Guggenheim lowered their target price on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Wedbush increased their price target on Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus target price of $32.85.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $16.09 on Monday. The stock’s 50 day moving average is $20.08 and its 200 day moving average is $20.12. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $107.77. The firm has a market cap of $1.69 billion, a P/E ratio of -1.91, a P/E/G ratio of 0.24 and a beta of 0.42. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The firm had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business’s revenue for the quarter was down 32.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.90 EPS. As a group, research analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Insider Activity

In related news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This trade represents a 6.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SRPT. AQR Capital Management LLC increased its position in shares of Sarepta Therapeutics by 454.6% during the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after acquiring an additional 6,390,860 shares in the last quarter. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 18.1% during the 3rd quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock valued at $208,452,000 after purchasing an additional 1,657,267 shares during the last quarter. First Trust Advisors LP increased its holdings in Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after purchasing an additional 1,312,220 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Sarepta Therapeutics by 183.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock worth $33,627,000 after purchasing an additional 1,129,610 shares during the last quarter. Finally, Erste Asset Management GmbH lifted its holdings in shares of Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after purchasing an additional 1,064,530 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.